Featured Research

from universities, journals, and other organizations

Researchers Confirm Vioxx Nearly Doubled Cardiovascular Risks In Cancer Prevention Study

Date:
February 23, 2005
Source:
University Of Texas M. D. Anderson Cancer Center
Summary:
The largest prospective trial ever examining the anti-inflammatory drug Vioxx as a chemoprevention agent found that the risk of developing a cardiovascular “event” –– heart attacks and/or strokes –– was almost double in patients who received the drug, compared to patients who took the placebo, according to a study out Feb. 15 online in The New England Journal of Medicine.

The largest prospective trial ever examining the anti-inflammatory drug Vioxx as a chemoprevention agent found that the risk of developing a cardiovascular “event” –– heart attacks and/or strokes –– was almost double in patients who received the drug, compared to patients who took the placebo, according to a study out Feb. 15 online in The New England Journal of Medicine.

The risk was first discovered and reported last September by the study’s safety monitoring board and led to the shutdown of the colon cancer chemoprevention trial and subsequent withdrawal of the drug from the U.S. market.

The trial, known as APPROVe (Adenomatous Polyp Prevention on Vioxx), was the longest test yet of Vioxx as a chemoprevention agent, and was designed to determine whether the drug could prevent the re-growth of precancerous colon polyps in people who had already had polyps removed. The prospective chemoprevention study randomized 2,586 participants from 108 centers in 29 countries to receive either 25 mgs. of Vioxx daily or a placebo drug for three years, 2001-2004. The trial was stopped September 30, 2004 –– approximately two months before its planned completion.

According to Robert S. Bresalier, M.D., of The University of Texas M. D. Anderson Cancer Center and lead author of The New England Journal of Medicine study, 46 of the 1287 patients randomized to take Vioxx daily had confirmed cardiovascular events over a three year period –– mostly heart attacks or strokes. In the 1,299 patients given a placebo drug, there were 26 events. Each group, however, had the same number of deaths and not all were related to heart attacks or strokes.

“The overall number of cardiovascular events is small, but, nevertheless, the difference between the groups is significant,” says Bresalier, who is professor and chair of the Department of Gastrointestinal Medicine and Nutrition at M. D. Anderson and a member of the study’s steering committee.

This study examined data on the 2,586 patients enrolled in the trial, all of whom had a history of adenomatous colon polyps. The most notable trend, according to Bresalier, was that patients did not begin to experience cardiovascular problems such as heart attacks or strokes until after 18 months of treatment. “In the first 18 months, the risks for the two treatments were similar,” Bresalier says.

Other cardiac problems, such as hypertension-related events, pulmonary edema and congestive heart failure-related events were much more prevalent in the Vioxx-treated group compared to the placebo group and presented earlier. The data on these cases, however, is less firm, Bresalier notes, because, unlike heart attacks or strokes, these problems were not “adjudicated,” or validated by a separate committee. This was not a cardiovascular trial, reminds Bresalier, so while investigators reported all events, only the most serious were fully examined.

"Because patient benefit is the most important criteria for any study, it was appropriate to stop the trial,” Bresalier says. “We don’t know why Vioxx increased this risk, but we now have an opportunity to study whether subpopulations of patients are more susceptible than others.”

“I think it’s unfortunate that we’ve perhaps lost a class of drugs which potentially has very important roles in a variety of diseases arthritis, cancer prevention, cancer treatment, treatment of Alzheimer’s disease, treatment of precancerous lesions, not only in the colon but in the esophagus and many other organs,” says Bresalier. “What we don’t know is, if the cardiovascular results seen in Vioxx represents a class effect of COX-2 inhibitors or if this is an individual effect to this drug. I don’t think we can tell this from this one trial or from the trials that are out there at the moment. That’s going to be the real question.”

The investigators examined the use of cardio-protective aspirin among patients and found that it did not skew findings on the overall risk of Vioxx treatment.

The study was funded by Merck Research Laboratories, which manufactures Vioxx. Bresalier reports receiving a consulting fee as a member of the APPROVe trial steering committee.


Story Source:

The above story is based on materials provided by University Of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas M. D. Anderson Cancer Center. "Researchers Confirm Vioxx Nearly Doubled Cardiovascular Risks In Cancer Prevention Study." ScienceDaily. ScienceDaily, 23 February 2005. <www.sciencedaily.com/releases/2005/02/050218131255.htm>.
University Of Texas M. D. Anderson Cancer Center. (2005, February 23). Researchers Confirm Vioxx Nearly Doubled Cardiovascular Risks In Cancer Prevention Study. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2005/02/050218131255.htm
University Of Texas M. D. Anderson Cancer Center. "Researchers Confirm Vioxx Nearly Doubled Cardiovascular Risks In Cancer Prevention Study." ScienceDaily. www.sciencedaily.com/releases/2005/02/050218131255.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins